Call 999 or go to your nearest A&E immediately if you experience: Severe abdominal pain with vomiting that does not settle this may indicate pancreatitis or a serious gallbladder problem Signs of a severe allergic reaction (anaphylaxis) including swelling of the face, lips, or throat, difficulty breathing, or a widespread rash Severe dehydration with inability to keep any fluids down Contact NHS 111 or seek urgent medical advice if you experience: Sudden pain in the upper right abdomen, fever, jaundice, pale stools, or dark urine possible signs of gallbladder disease Persistent vomiting or diarrhoea that is preventing adequate fluid intake Contact your GP or specialist if you experience: Persistent or troublesome nausea, vomiting, or abdominal discomfort that does not resolve with time Significant changes in mood, including low mood or anxiety, which may be associated with rapid weight loss or hormonal shifts Noticeable and sustained changes in libido or sexual function that are causing distress Irregular menstrual cycles or new hormonal symptoms Symptoms of hypoglycaemia shakiness, sweating, confusion, or palpitations particularly if you are also taking insulin or a sulfonylurea Any injection site reactions that worsen, become infected, or do not resolve Concerns about dehydration or reduced urine output following persistent gastrointestinal symptoms Changes in libido, whilst not confirmed as a direct side effect of retatrutide, are worth discussing with a GP if they are persistent, distressing, or accompanied by other symptoms
Matcha helps reduce skin inflammation and redness
Copyright, 2024
Beyond appetite regulation, GLP-1 medications enhance insulin secretion in response to meals while suppressing glucagon release, improving overall glycemic control
The following are frequently asked questions (FAQ) regarding the 2023 OMA publication entitled: Compounded peptides: An Obesity Medicine Association Position Statement. This follow-up Commentary FAQ concludes with a Call for Action such that applicable stakeholders (e.g., clinicians, pharmaceutical companies, compounding pharmacists, and the Food and Drug Administration) are unified in ensuring that patients living with the disease of obesity have access to safe and effective anti-obesity medications, even during times of peptide anti-obesity medication shortages
.png)
